Pages that link to "Q34474204"

The following pages link to Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments (Q34474204):

Displaying 25 items.

• Human ASH1 expression in prostate cancer with neuroendocrine differentiation (Q24319673) (← links)
• Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure (Q26859201) (← links)
• Distinct genetic alterations in small cell carcinoma from different anatomic sites (Q27008242) (← links)
• T-type calcium channels blockers as new tools in cancer therapies (Q28306311) (← links)
• Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression (Q30432236) (← links)
• Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle (Q33356928) (← links)
• Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer (Q33650205) (← links)
• Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression (Q33732496) (← links)
• Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells (Q33957249) (← links)
• The role of epithelial plasticity in prostate cancer dissemination and treatment resistance (Q34505037) (← links)
• Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients (Q35380936) (← links)
• Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model (Q36143611) (← links)
• Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers (Q36782301) (← links)
• EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway (Q36882764) (← links)
• Platinum-based chemotherapy for variant castrate-resistant prostate cancer (Q36977870) (← links)
• Modeling a lethal prostate cancer variant with small-cell carcinoma features (Q37582049) (← links)
• Small cell carcinoma of the prostate (Q38188869) (← links)
• Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review (Q38209356) (← links)
• Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. (Q38442842) (← links)
• Factors implicated in radiation therapy failure and radiosensitization of prostate cancer (Q38807901) (← links)
• Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. (Q39905772) (← links)
• Transcriptional activation of the human gastrin-releasing peptide receptor gene in gastrointestinal and prostatic epithelial cancer cells (Q40535794) (← links)
• Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate (Q42151444) (← links)
• Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity (Q43010807) (← links)
• Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer (Q58327426) (← links)